Remission Duration and Long-Term Outcomes in Patients with Moderate-to-Severe Psoriasis Treated by Biologics or Tofacitinib in Controlled Clinical Trials: A 15-Year Single-Center Experience

INTRODUCTION: Relapse is common after treatment discontinuation for patients with moderate-to-severe psoriasis. The objective of this study was to understand the remission duration and long-term outcomes in psoriasis patients after biologic withdrawal. METHODS: We retrospectively included the follow...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yi-Wei, Tsai, Tsen-Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704191/
https://www.ncbi.nlm.nih.gov/pubmed/31270683
http://dx.doi.org/10.1007/s13555-019-0310-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704191/
https://www.ncbi.nlm.nih.gov/pubmed/31270683
http://dx.doi.org/10.1007/s13555-019-0310-5

Ejemplares similares